首页> 外文期刊>Cell and Tissue Research >Comparative microarray analysis of microRNA expression profiles in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases, and benign melanocytic nevi
【24h】

Comparative microarray analysis of microRNA expression profiles in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases, and benign melanocytic nevi

机译:在原发性皮肤恶性黑色素瘤,皮肤恶性黑色素瘤转移和良性黑素细胞痣中microRNA表达谱的比较微阵列分析

获取原文
获取原文并翻译 | 示例
           

摘要

Perturbations in microRNA (miRNA) expression profiles have been reported for cutaneous malignant melanoma (CMM) predominantly when examined in cell lines. Despite the rapidly growing number of newly discovered human miRNA sequences, the availability of up-to-date miRNA expression profiles for clinical samples of primary cutaneous malignant melanoma (PCMM), cutaneous malignant melanoma metastases (CMMM), and benign melanocytic nevi (BMN) is limited. Specimens excised from the center of tumors (lesional) from patients with PCMM (n=9), CMMM (n=4), or BMN (n=8) were obtained during surgery. An exploratory microarray analysis was performed by miRNA expression profiling based on Agilent platform screening for 1205 human miRNAs. The results from the microarray analysis were validated by TaqMan quantitative real-time polymerase chain reaction. In addition to several miRNAs previously known to be associated with CMM, 19 unidentified miRNA candidates were found to be dysregulated in CMM patient samples. Among the 19 novel miRNA candidates, the genes hsa-miR-22, hsa-miR-130b, hsa-miR-146b-5p, hsa-miR-223, hsa-miR-301a, hsa-miR-484, hsa-miR-663, hsa-miR-720, hsa-miR-1260, hsa-miR-1274a, hsa-miR-1274b, hsa-miR-3663-3p, hsa-miR-4281, and hsa-miR-4286 were upregulated, and the genes hsa-miR-24-1*, hsa-miR-26a, hsa-miR-4291, hsa-miR-4317, and hsa-miR-4324 were downregulated. The results of this study partially confirm previous CMM miRNA profiling studies identifying miRNAs that are dysregulated in CMM. However, we report several novel miRNA candidates in CMM tumors; these miRNA sequences require further validation and functional analysis to evaluate whether they play a role in the pathogenesis of CMM.
机译:皮肤恶性黑色素瘤(CMM)的microRNA(miRNA)表达概况出现了扰动,主要是在细胞系中检测到的。尽管新发现的人类miRNA序列的数量迅速增长,但针对原发性皮肤恶性黑色素瘤(PCMM),皮肤恶性黑色素瘤转移瘤(CMMM)和良性黑素细胞痣(BMN)的临床样品,最新的miRNA表达谱的可用性是有限的。在手术期间从PCMM(n = 9),CMMM(n = 4)或BMN(n = 8)的患者的肿瘤(病灶)中心切除了标本。基于安捷伦平台筛选的1205个人miRNA,通过miRNA表达谱进行了探索性微阵列分析。通过TaqMan定量实时聚合酶链反应验证了微阵列分析的结果。除了先前已知与CMM相关的几种miRNA,在CMM患者样品中发现了19种未鉴定的miRNA候选物失调。在19种新颖的miRNA候选基因中,基因hsa-miR-22,hsa-miR-130b,hsa-miR-146b-5p,hsa-miR-223,hsa-miR-301a,hsa-miR-484,hsa-miR -663,hsa-miR-720,hsa-miR-1260,hsa-miR-1274a,hsa-miR-1274b,hsa-miR-3663-3p,hsa-miR-4281和hsa-miR-4286被上调,并下调了hsa-miR-24-1 *,hsa-miR-26a,hsa-miR-4291,hsa-miR-4317和hsa-miR-4324基因。这项研究的结果部分证实了先前的CMM miRNA分析研究,该研究确定了CMM中失调的miRNA。但是,我们报道了CMM肿瘤中的几种新型miRNA候选物。这些miRNA序列需要进一步验证和功能分析,以评估它们是否在CMM的发病机理中起作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号